Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CHUK	1147	CHEMBL592893	CHEMBL592893	inhibitor	GuideToPharmacologyInteractions
CHUK	1147	ASCORBATE	CHEMBL196		NCI	11120850
CHUK	1147	AMINOSALICYLIC ACID	CHEMBL1169	inhibitor	DrugBank	11054378, 11151876, 12950415
CHUK	1147	CHEMBL608538	CHEMBL608538	inhibitor	GuideToPharmacologyInteractions
CHUK	1147	MESALAMINE	CHEMBL704	inhibitor	TdgClinicalTrial, DrugBank	11054378, 11151876, 12950415
CHUK	1147	BMS-345541	CHEMBL249697	allosteric modulator	GuideToPharmacologyInteractions
CHUK	1147	SULFASALAZINE	CHEMBL421	inhibitor	DrugBank	11054378, 12950415
CHUK	1147	ACETYLCYSTEINE	CHEMBL600	inhibitor	DrugBank	10788610

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CHUK	rs11591741	CC + CG	ustekinumab	efficacy	yes	as measured by PASI75 at 4 months and adjusted for weight and FDR. Caution this is C/G SNP in gene on minus strand, it appeared from looking at other minus strand genes that all variants in the paper were measured on plus strand so results are reported as stated as in the paper and not complemented.	Genotypes CC + CG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG.	27977334	1448594399
CHUK	rs11591741	G	Tumor necrosis factor alpha	efficacy	yes	The G allele was associated with less improvement in Disease Activity Score 28 (DAS28) score between baseline and 3 months of treatment as compared to the C allele. No significant result was seen at 6 months of treatment (p=1.0).	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	25896535	1448423378